Description: Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops precision oncology medicines. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1/2 for use in the treatment of platinum-resistant ovarian cancer; endometrial and bladder cancer; and SCCs, including SCCHN, cervical, and anal cancer. It is also developing two preclinical drug programs used to predict tumor sensitivity based on custom OncoSignature tests. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Home Page: www.acrivon.com
ACRV Technical Analysis
480 Arsenal Way
Watertown,
MA
02472
United States
Phone:
617 207 8979
Officers
| Name | Title |
|---|---|
| Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer |
| Ms. Kristina Masson Ph.D. | Co-Founder, Exec. VP of Bus. Operations, Treasurer, Sec. & Director |
| Dr. Eric J. Devroe Ph.D. | Chief Operating Officer |
| Mr. Erick Gamelin M.D., Ph.D. | Chief Medical Officer |
| Mr. Rasmus Holm-Jorgensen | Chief Financial Officer |
| Ms. Katharine Peterson CPA | VP of Fin. & Accounting |
| Mr. Bruce Close | VP of Quality & Compliance |
| Ms. Mary-Alice Miller J.D. | Gen. Counsel |
| Ms. Crystal Mercado | Global Head of HR |
| Dr. Jesper V. Olsen Ph.D. | Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-11-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 39 |